Irene Stefanaki

ORCID: 0000-0002-2964-370X
Publications
Citations
Views
---
Saved
---
About
Contact & Profiles
Research Areas
  • Cutaneous Melanoma Detection and Management
  • melanin and skin pigmentation
  • Psoriasis: Treatment and Pathogenesis
  • Skin Protection and Aging
  • Dermatology and Skin Diseases
  • Melanoma and MAPK Pathways
  • Nonmelanoma Skin Cancer Studies
  • Mast cells and histamine
  • Asthma and respiratory diseases
  • Immunotherapy and Immune Responses
  • Autoimmune Bullous Skin Diseases
  • Allergic Rhinitis and Sensitization
  • Syphilis Diagnosis and Treatment
  • Cervical Cancer and HPV Research
  • Reproductive tract infections research
  • Cancer Genomics and Diagnostics
  • Urinary and Genital Oncology Studies
  • HIV, TB, and STIs Epidemiology
  • Cutaneous lymphoproliferative disorders research
  • Genital Health and Disease
  • Olfactory and Sensory Function Studies
  • Genetic Associations and Epidemiology
  • Nail Diseases and Treatments
  • Infectious Diseases and Mycology
  • Antifungal resistance and susceptibility

Andreas Sygros Hospital
2014-2025

National and Kapodistrian University of Athens
2014-2025

Laiko General Hospital of Athens
2018

Max Planck Institute for Molecular Genetics
2011-2014

Academy of Athens
2014

Johannes Gutenberg University Mainz
2011-2014

Biomedical Research Foundation
2014

Mère et Enfant en Milieu Tropical
2013

Freie Universität Berlin
2011

Massachusetts General Hospital
2011

Psoriasis is a chronic, autoinflammatory cutaneous disorder affecting any area of the human body. Scalp involvement major cause social and emotional distress, negatively quality life [1]. Successful management scalp psoriasis can be very challenging, primarily due to difficulties arising from chronic application topical agents disease's refractory nature Therapeutic options for patients suffering moderate-to-severe plaque have expanded considerably in recent years with emergence novel...

10.1111/ijd.17658 article EN International Journal of Dermatology 2025-01-16

Background Topical application of 5-aminolaevulinic acid (ALA) to condylomata acuminata leads accumulation protoporphyrin IX (PpIX); therefore ALA-induced photodynamic therapy (ALA-PDT) appears be a potential treatment. Objectives To investigate in vivo the PpIX fluorescence time course after topical ALA order determine optimal for irradiation, and assess efficacy subsequently performed ALA-PDT. Methods Fluorescence kinetics was studied 12 male patients with acuminata. Confirmation diagnosis...

10.1111/j.1365-2133.2003.05553.x article EN British Journal of Dermatology 2003-11-01

Abstract Background Since the year 2000 a melanoma/skin cancer screening campaign has been organized annually in Greece context of Euromelanoma Screening Day Campaign. Objectives We aimed to analyse characteristics screened population, recognize relevant risk factors and identify cases histologically confirmed malignant melanoma (MM) individuals with suspicious skin lesions. Methods An analysis completed forms from years 2000–2004 was performed respect demographic, epidemiological clinical...

10.1111/j.1468-3083.2006.01865.x article EN Journal of the European Academy of Dermatology and Venereology 2006-11-16

Background Genetic association studies have revealed numerous polymorphisms conferring susceptibility to melanoma. We aimed replicate previously discovered melanoma-associated single-nucleotide (SNPs) in a Greek case-control population, and examine their predictive value. Methods Based on field synopsis of genetic variants melanoma (MelGene), we genotyped 284 patients controls at 34 SNPs which 19 derived from GWAS. tested each one the 33 passing quality control for with both without...

10.1371/journal.pone.0055712 article EN cc-by PLoS ONE 2013-02-05

Brodalumab, a fully human IgG2k antibody blocking the receptor of IL17, is characterized by rapid onset action with high skin clearance rates in clinical trials. Since setting PASI90/100 or absolute PASI ≤ 3 as treatment goals have become attainable, evaluating effectiveness and safety profile biologic agents, such brodalumab, real-world essential.The aim this study was to evaluate brodalumab over period 104 weeks everyday practice. Clinical predictive factors initial (week 12/16) response...

10.1111/jdv.18825 article EN Journal of the European Academy of Dermatology and Venereology 2022-12-23

Journal Article Comprehensive mutational analysis of CDKN2A and CDK4 in Greek patients with cutaneous melanoma Get access V. Nikolaou, Nikolaou Department Dermatology, University Athens Medical School, 'A. Sygros' Hospital, I Dragoumi 5, 16121 Athens, Greece Search for other works by this author on: Oxford Academic Google Scholar X. Kang, Kang Wellman Center Photomedicine, MGH Cancer Center, Massachusetts General 55 Fruit Street, Boston, MA, U.S.A. A. Stratigos, Stratigos H. Gogas, Gogas...

10.1111/j.1365-2133.2011.10551.x article EN British Journal of Dermatology 2011-08-01

Abstract Background Most of large epidemiological studies on melanoma susceptibility have been conducted fair skinned individuals (US, Australia and Northern Europe), while Southern European populations, characterized by high UV exposure dark‐skinned individuals, are underrepresented. Objectives We report a comprehensive pooled analysis established high‐ intermediate‐penetrance genetic variants clinical characteristics Mediterranean families from the MelaNostrum Consortium. Methods Pooled...

10.1111/jdv.19461 article EN cc-by-nc Journal of the European Academy of Dermatology and Venereology 2023-08-23

Journal Article p53 codon 72 Pro homozygosity increases the risk of cutaneous melanoma in individuals with dark skin complexion and among noncarriers melanocortin 1 receptor red hair variants Get access I. Stefanaki, Stefanaki Department Dermatology, University Athens, A. Sygros Hospital, Dragoumi 5, 16121 Greece *Medical Genetics, Agia Sophia Children's †Department Internal Medicine, Laikon ‡Department Plastic Surgery Microsurgery, Gennimatas General ¶Contributed equally as first authors...

10.1111/j.1365-2133.2006.07645.x article EN British Journal of Dermatology 2006-12-14

Efalizumab (anti-CD11a antibody) targets T cell-mediated steps important in the immunopathogenesis of psoriasis. As efalizumab is intended to be administered on a continuous long-term basis psoriasis, it share experience concerning issues commonly occurring during its use real daily practice.To evaluate efficacy and safety treatment Greek patients with moderate-to-severe plaque investigate whether there are specific characteristics that predict clinical outcome therapy.Seventy-two who had...

10.1111/j.1365-2133.2007.07764.x article EN British Journal of Dermatology 2007-03-16
Coming Soon ...